Exposure‐response Relationships for the Efficacy and Safety of Filgotinib and Its Metabolite GS‐829845 in Subjects with Rheumatoid Arthritis Based on Phase 2 and Phase 3 Studies
British Journal of Clinical Pharmacology（2022）
Key words
drug safety,PK-PD,randomized controlled trial,rheumatoid arthritis,therapeutics,Specialties,filgotinib,JAK inhibitors,exposure-response
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined